Iranian company develops homegrown treatment for diabetic foot ulcers and burns

An Iranian knowledge-based company has successfully developed a domestically produced medication for treating diabetic foot ulcers and burns, marking a significant advancement in the country’s biotechnology sector. 

The drug, known as Bornamin, is based on epidermal growth factor and is particularly effective for third and fourth-degree burns as well as diabetic wounds. 

According to Fahimeh Mohammad Hosseini, CEO of Borna Biopharma, this innovation not only enhances treatment options but also offers substantial economic benefits, helping save approximately 25 million tomans per unit in foreign currency costs. 

Previously, similar foreign medications were priced at around 300 pounds, making them expensive for many patients. 

The local production of Bornamin allows the drug to be sold for just 2.5 million tomans per unit. The product is available in both injectable and topical forms, with the topical variant already on the market and the injectable version awaiting regulatory approval from the Iranian Food and Drug Administration. 

This breakthrough is expected to improve the quality of life for many Iranian patients suffering from diabetes-related complications.